Treatment by BAALC expression group
. | Low BAALC n = 43 . | High BAALC n = 43 . | P . |
|---|---|---|---|
| Induction chemotherapy, n (%) | |||
| ADE* | 20 (47) | 20 (47) | |
| ADE* plus PSC-833 | 23 (53) | 23 (53) | .99 |
| Consolidation therapy | |||
| Auto PBSCT,† n (%) | 23 (66) | 25 (76) | .43 |
| Maintenance therapy | |||
| Subcutaneous IL-2,† n (%) | 16 (46) | 17 (52) | .81 |
| Salvage therapy | |||
| Primary refractory or relapsed patients, n | 18 | 27 | |
| Autologous PBSCT, n (%) | 1 (6) | 1 (4) | |
| Allogeneic SCT, n (%) | 3 (17) | 5 (19) | |
| No SCT outside of first CR, n (%) | 14 (78) | 21 (78) | .99 |
. | Low BAALC n = 43 . | High BAALC n = 43 . | P . |
|---|---|---|---|
| Induction chemotherapy, n (%) | |||
| ADE* | 20 (47) | 20 (47) | |
| ADE* plus PSC-833 | 23 (53) | 23 (53) | .99 |
| Consolidation therapy | |||
| Auto PBSCT,† n (%) | 23 (66) | 25 (76) | .43 |
| Maintenance therapy | |||
| Subcutaneous IL-2,† n (%) | 16 (46) | 17 (52) | .81 |
| Salvage therapy | |||
| Primary refractory or relapsed patients, n | 18 | 27 | |
| Autologous PBSCT, n (%) | 1 (6) | 1 (4) | |
| Allogeneic SCT, n (%) | 3 (17) | 5 (19) | |
| No SCT outside of first CR, n (%) | 14 (78) | 21 (78) | .99 |